Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Shaocheng Lyu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2757-7868; OpenAlex author ID A5078834388, A5125747982. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 8 papers · 2024: 1 paper · 2025: 4 papers · 2026: 5 papers

Papers 22

  1. Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer. Last author DOI 10.1016/j.hbpd.2026.05.001↗
  2. The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC. Co-author DOI 10.1038/s41598-026-51645-1↗
  3. Comprehensive comparisons of total pancreatectomy versus pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a double-center, retrospective study. Co-author DOI 10.21037/gs-2025-aw-544↗
  4. Correction: Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adeno… Co-author DOI 10.3389/fonc.2026.1852367↗
  5. Androgen-induced gene 1 correlates with extracellular vesicle-associated cholesterol metabolism and hepatic metastasis of pancreatic cancer Co-author DOI 10.3748/wjg.121007↗
  6. A logistic regression model to predict long-term survival for borderline resectable pancreatic cancer patients with upfront surgery. First author DOI 10.1186/s40644-025-00830-y↗
  7. Organ-specific role of neutrophil extracellular traps in shaping the postoperative thrombo-inflammatory niche in pancreatic ductal adenocarcinoma: a multi-mode… Co-author DOI 10.3389/fimmu.2025.1728391↗
  8. Prognostic implications of venous invasion in pancreatic cancer following radical surgical resection: a pathological perspective. Co-author DOI 10.3389/fmed.2025.1613153↗
  9. Development and validation of a predictive model for portal-systemic venous invasion grading in borderline resectable pancreatic cancer. Last author DOI 10.3748/wjg.v31.i42.112354↗
  10. Influence of sarcopenia on postoperative complications and long-term survival in pancreatic cancer patients undergone pancreaticoduodenectomy. Co-author DOI 10.3389/fnut.2024.1434630↗
  11. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11032-9↗
  12. Prognostic value of perioperative serum low-density lipoprotein cholesterol level for postoperative prognosis of pancreatic cancer: a retrospective study. Co-author DOI 10.1186/s12944-023-01851-x↗
  13. Derivation and validation of a nomogram model for venous thromboembolism in patients undergoing borderline resectable pancreatic cancer surgery Co-author DOI 10.21203/rs.3.rs-2469113/v1↗
  14. Effect of the preoperative prognostic nutritional index on the long-term prognosis in patients with borderline resectable pancreatic cancer after pancreaticodu… Co-author DOI 10.3389/fonc.2023.1098459↗
  15. Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1112576↗
  16. A nomogram model to predict the portal vein thrombosis risk after surgery in patients with pancreatic cancer. Co-author DOI 10.3389/fsurg.2023.1293004↗
  17. Prognostic Value for Perioperative Serum Total Cholesterol Level on Postoperative Long-Term Prognosis of Pancreatic Cancer: A Retrospective Clinical Study. Co-author DOI 10.3390/diagnostics13081402↗
  18. Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer. Last author DOI 10.3390/diagnostics13193126↗
  19. Without compromising surgical outcomes, neoadjuvant therapy might be a better approach to improve the prognosis of patients with advanced pancreatic cancer. Co-author DOI 10.21037/gs-2021-06↗
  20. Prognostic Value of Preoperative NLR and Vascular Reconstructive Technology in Patients With Pancreatic Cancer of Portal System Invasion: A Real World Study. Co-author DOI 10.3389/fonc.2021.682928↗
  21. Triptolide inhibits pancreatic cancer cell proliferation and migration via down-regulating PLAU based on network pharmacology of Tripterygium wilfordii Hook F. Co-author DOI 10.1016/j.ejphar.2020.173225↗
  22. Application of preoperative three-dimensional model design in radioactive particle implantation for advanced pancreatic cancer. First author DOI 10.2147/ott.s164880↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ren Lang · 20 shared papers, 2020–2026 · strength 4.86
  2. Qiang He · 7 shared papers, 2023–2026 · strength 2.08
  3. Jincan Huang · 7 shared papers, 2023–2025 · strength 1.75
  4. Han-Xuan Wang · 6 shared papers, 2023–2025 · strength 1.45
  5. Fang-Fei Wang · 3 shared papers, 2025–2026 · strength 0.96
  6. Songping Cui · 4 shared papers, 2023–2025 · strength 0.92
  7. Fangfei Wang · 3 shared papers, 2023–2026 · strength 0.78
  8. Jing Wang · 4 shared papers, 2021–2023 · strength 0.77
  9. Xin Zhao · 3 shared papers, 2023–2025 · strength 0.70
  10. Xin Zhao · 2 shared papers, 2026 · strength 0.61
  11. Qiang He · 3 shared papers, 2021–2025 · strength 0.60
  12. Di Wang · 2 shared papers, 2023–2025 · strength 0.51
  13. Zhangyong Ren · 3 shared papers, 2020–2023 · strength 0.48
  14. Xinxue Zhang · 2 shared papers, 2021–2023 · strength 0.36
  15. Weiwei Shao · 1 shared paper, 2026 · strength 0.33
  16. Yun-Zhao Luo · 1 shared paper, 2026 · strength 0.32
  17. Tao Jiang · 1 shared paper, 2025 · strength 0.30
  18. Jing Wang · 1 shared paper, 2025 · strength 0.30
  19. Guangzhen Qu · 1 shared paper, 2024 · strength 0.28
  20. Zhangyong Ren · 1 shared paper, 2026 · strength 0.28
  21. Zhe Liu · 2 shared papers, 2020–2023 · strength 0.28
  22. Cheng Ding · 1 shared paper, 2023 · strength 0.22
  23. Qing Chen · 1 shared paper, 2023 · strength 0.20
  24. Lin Zhou · 1 shared paper, 2021 · strength 0.14
  25. Li-chao Pan · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.